ArticleChemMedChem2026
Development and Characterization of a Noncovalent Stimulator of Interferon Genes Proteolysis-Targeting Chimeras.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic targeting of the cGAS-STING pathway in human disease.The Journal of clinical investigation · 2026Review
- Development and Characterization of a Noncovalent Stimulator of Interferon Genes Proteolysis-Targeting Chimeras.ChemMedChem · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway activates the immune response upon detection of cytosolic dsDNA and is a key regulator of innate immunity. Overactivation of cGAS-STING has been implicated in numerous inflammatory diseases, and inhibition of cGAS-STING signaling has attracted significant interest as a therapeutic approach to attenuate aberrant inflammation. Proteolysis-targeting chimeras (PROTACs) have become popular modalities for catalyzing the degradation of proteins of interest, thus inhibiting their function. Herein, the design, synthesis, and characterization of noncovalent catalytic STING PROTACs based on a known diphenyl-dihydroisoquinolone STING inhibitory chemotype are reported. The lead from this series (BH690L) exhibits an effective concentration for half-maximal degradation (DC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.